Comprehensive NSCLC Panel 1

What is Comprehensive NSCLC Panel test?

Comprehensive NSCLC Panel is a combination of 13 key mutations in lung cancer along with PDL1- DAKO 22C3 testing. NSCLC stands for Non-Small Cell Lung Cancer, which is the most prevalent type of lung cancer in India. NSCLC panel is an NGS based test which offers complete genotyping solutions by amazing 13 genes relevant to lung cancer. It typically covers EGFR, ALK, ROS1, BRAF, MET, RET, ERBB2/HER2, KRAS and NTRK1/2/3, alongside other actionable or resistance‑associated genes.

PDL1 22C3 Dako is an immunohistochemistry test performed on tumor tissue to measure PDL1 protein expression, primarily to guide use of pembrolizumab (Keytruda) immunotherapy as a FDA‑cleared companion diagnostic in several cancers. It reports PDL1 using validated scoring algorithms such as Tumor Proportion Score (TPS) and/or Combined Positive Score (CPS) depending on tumor type, helping identify patients more likely to benefit from PD‑1/PDL1 blockade.

What is Comprehensive NSCLC Panel test?

Clinicians should consider & recommend NSCLC Panel for-

• Comprehensive therapy guidance as it assesses relevant 13 genes & PDL1 DAKO 22C3 (fro immunotherapy) related to NSCLC to match patients to approved targeted therapies and trials.
• Consolidates multiple single‑gene tests into one assay, conserving limited tissue and shortening time to a clinically actionable, tumor‑board‑ready report.
• Detects resistance mutations at progression and samples tumor heterogeneity more effectively than sequential testing, supporting dynamic treatment adaptation.

Why consider Comprehensive NSCLC Panel test?

Comprehensive NSCLC Panel tests identifies specific genetic mutations and PD-L1 expression in Non-Small Cell Lung Cancer (NSCLC) patients to guide targeted therapy selection, which can lead to more effective treatment and better patient outcomes.

Who should get this Comprehensive NSCLC Panel test?

Clinicians should consider & recommend NSCLC Panel for-

• Newly diagnosed stage III/IV non‑squamous NSCLC (and squamous with clinical features suggesting a driver, such as younger age or minimal smoking) where broad, upfront testing can match to targeted therapies or trials.
• Cases with limited tissue or when rapid results are crucial, where a single panel conserves sample and shortens time to an actionable, tumor‑board‑ready report.
• Patients progressing on targeted therapy who need resistance profiling (e.g., EGFR, ALK, ROS1, MET mechanisms) to guide the next line of treatment.
• Individuals considered for immunotherapy or combination strategies, where panel results help contextualize choices alongside PD‑L1 and clinical factors.

More Information about Comprehensive NSCLC Panel test

NSCLC stands for non-small cell lung cancer, the most common category of lung cancer that includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, and is managed with combinations of surgery, radiation, chemotherapy, targeted therapy, and immunotherapy based on stage and biomarkers. NSCLC (non-small cell lung cancer) is the most common type of lung cancer, making up about 80% of all lung cancer cases. It is a broad term for several types of epithelial lung cancers, with the main subtypes being adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. 

Other names: NSCLC panel; NSCLC test, Lung cancer targeted panel; NSCLC comprehensive genomic profiling (CGP) panel; Lung cancer panel, Lung cancer profiler next, Lung cancer NGS panel, Lung cancer 13 gene panel, NSCLC panel with PDL1, Lung cancer panel with PDL1 Dako, Lung cancer panel with PDL1 Dako 22C3, NSCLC panel with PDL1 Dako,